Eucreas is a combination of metformin, which decreases the production of sugar by the liver and increases insulin sensitivity, and galvus, a member of DPP-4 inhibitors associated with liver problems.
Novartis said: “The approval comes after the company proposed changes to the EU label recommending that liver monitoring should be conducted.”